CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,179 enrolled
Drug / intervention
Parathyroid Hormone (PTH) (1-84)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00478569
NCT00478569N/ACompleted

Adherence to PTH(1-84) Treatment in Europe. A Non-interventional Cohort Study Collecting Safety Information and Examining Reasons and Predictors for Adherence to PTH(1-84) Treatment in Usual Clinical Settings

Takeda·observational·Posted May 25, 2007·Updated May 28, 2014

In Brief

An observational study evaluating Parathyroid Hormone (PTH) (1-84) for Clinical Use of PTH(1-84). Completed, enrolled 1,179 participants across 1 site.

Detailed Summary

The primary objective is: 1\) to describe adherence (and the main factors influencing adherence) to PTH(1-84) treatment when prescribed in a normal clinical setting. The secondary objectives are: 1. to describe the demographics and clinical characteristics of the patients that in a normal clinical setting are started on a treatment regimen with PTH(1-84) 2. to describe (using available data) the long term treatment effectiveness during the 24 months following initiation of PTH(1-84) treatment in a normal clinical setting 3. to monitor safety for 24 months following initiation of PTH(1-84) treatment in a patient in a normal clinical setting.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesDenmark
Collaborators--

Timeline

N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 25, 2007
Enrollment StartApr 1, 2007
Primary CompletionMar 1, 2013
TodayJul 2, 2026
Enrollment to primary: 5.9 yearsPosted 19.1 years ago

Interventions

Parathyroid Hormone (PTH) (1-84)drug

Adherence to PTH(1-84) treatment in Usual Clinical Settings